NOBILI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.116
EU - Europa 8.992
AS - Asia 6.055
SA - Sud America 895
AF - Africa 174
OC - Oceania 123
Continente sconosciuto - Info sul continente non disponibili 2
Totale 28.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.960
RU - Federazione Russa 2.784
PL - Polonia 2.757
SG - Singapore 1.747
CN - Cina 1.391
IT - Italia 929
HK - Hong Kong 901
BR - Brasile 721
VN - Vietnam 679
IE - Irlanda 673
KR - Corea 510
SE - Svezia 481
DE - Germania 319
FI - Finlandia 283
FR - Francia 253
IN - India 194
GB - Regno Unito 171
JO - Giordania 125
JP - Giappone 122
AU - Australia 120
UA - Ucraina 90
ID - Indonesia 79
AR - Argentina 75
CA - Canada 72
BD - Bangladesh 66
TR - Turchia 64
NL - Olanda 48
ES - Italia 45
MX - Messico 45
IQ - Iraq 42
CH - Svizzera 40
ZA - Sudafrica 37
CI - Costa d'Avorio 35
AT - Austria 34
EC - Ecuador 31
BE - Belgio 28
NG - Nigeria 28
MA - Marocco 18
PK - Pakistan 18
CO - Colombia 17
EG - Egitto 14
VE - Venezuela 13
CL - Cile 12
PH - Filippine 12
DO - Repubblica Dominicana 11
PY - Paraguay 11
SA - Arabia Saudita 11
TH - Thailandia 11
GR - Grecia 8
IR - Iran 8
TN - Tunisia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
ET - Etiopia 7
LB - Libano 7
LT - Lituania 7
PE - Perù 7
DZ - Algeria 6
IL - Israele 6
KE - Kenya 6
MY - Malesia 6
SY - Repubblica araba siriana 6
KZ - Kazakistan 5
RO - Romania 5
BB - Barbados 4
BJ - Benin 4
CZ - Repubblica Ceca 4
NP - Nepal 4
OM - Oman 4
SC - Seychelles 4
TW - Taiwan 4
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
DK - Danimarca 3
GE - Georgia 3
HN - Honduras 3
JM - Giamaica 3
LV - Lettonia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BG - Bulgaria 2
BT - Bhutan 2
HU - Ungheria 2
MN - Mongolia 2
NI - Nicaragua 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SV - El Salvador 2
AM - Armenia 1
AO - Angola 1
BS - Bahamas 1
Totale 28.337
Salva come PNG Salva come JPEG
Città #
Warsaw 2.744
Santa Clara 2.423
Ashburn 1.355
Singapore 1.259
Fairfield 884
Hong Kong 736
Dublin 671
Chandler 669
Seoul 494
San Jose 482
Woodbridge 433
Cambridge 385
Seattle 380
Houston 376
Wilmington 319
Beijing 302
Hefei 272
Ann Arbor 225
The Dalles 211
Ho Chi Minh City 204
Buffalo 180
Altamura 179
Princeton 173
Lawrence 168
Florence 161
Lauterbourg 159
Dallas 149
Hanoi 141
Council Bluffs 140
Boston 135
Jacksonville 133
Moscow 133
Los Angeles 130
Helsinki 121
Tokyo 114
Melbourne 105
Mumbai 104
New York 93
Munich 91
Shanghai 87
Boardman 86
Medford 69
San Diego 67
Bremen 63
Kent 63
São Paulo 57
Jakarta 53
Paris 53
Clifton 49
Falls Church 47
Rome 42
Turku 42
Redondo Beach 38
Izmir 37
London 36
Abidjan 35
Bern 34
Haiphong 34
Phoenix 34
Da Nang 33
Dong Ket 32
Norwalk 31
Dearborn 30
Toronto 29
Frankfurt am Main 28
Orem 27
Vienna 27
Abuja 25
Chicago 25
Hillsboro 24
Guangzhou 23
Johannesburg 23
Brussels 22
Milan 22
Belo Horizonte 21
Rio de Janeiro 21
Lappeenranta 20
Bengaluru 19
Brooklyn 17
Denver 16
Montreal 16
West Jordan 16
Barcelona 15
Dhaka 15
Stockholm 15
Baghdad 14
Chennai 14
Hải Dương 14
Palermo 14
Tianjin 14
Amsterdam 13
Brasília 13
San Francisco 13
Andover 12
Curitiba 12
Pune 12
Catania 11
Guayaquil 11
Redmond 11
Bari 10
Totale 19.239
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 402
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 377
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 351
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 347
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 345
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 345
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 334
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 331
Natural compounds for cancer treatment and prevention 330
Emerging drugs in refractory colorectal cancer 327
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 327
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 316
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 314
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 309
Druggable Targets in Pancreatic Adenocarcinoma 305
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 304
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 303
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 301
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 290
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 279
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 264
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 247
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 243
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 243
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 242
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 231
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 230
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 225
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 218
Cellular pharmacology of gemcitabine. 218
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 213
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 212
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 209
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 206
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 205
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 204
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 200
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 199
Chronic inflammation in urothelial bladder cancer 198
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 196
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 193
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 191
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 190
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 189
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 186
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 185
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 185
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 180
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 180
Pharmacogenetics: Implementing personalized medicine 179
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 177
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 176
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 176
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 176
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 172
The clinical role of PIK3CA mutations in colorectal cancer 166
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 165
Establishment and characterization of a new spontaneously immortalized ER-/PR-/HER2+ human breast cancer cell line, DHSF-BR16 164
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 161
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 160
Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale 159
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 159
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 158
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways 157
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 157
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 156
Size dependent biological profiles of PEGylated gold nanorods 156
Pharmacological strategies for overcoming multidrug resistance. 154
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 154
Postoperative chemotherapy in resected gastric cancer: results of a single center experience. 154
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 154
Prognostic factors in primary and iterative surgery of colorectal liver metastases 153
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 153
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer 151
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 150
Pharmacokinetics of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs 148
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 148
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 146
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 145
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 145
Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer 145
The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. 145
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 144
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 144
Thymidylate synthase and orotate phosphoribosyl-transferase gene expression and genotype as predictors for clinical outcome in colorectal cancer patients treated with 5-fluorouracil 142
Alternative approaches to overcome multidrug resistance 142
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 142
Role of ATP-binding cassette transporters in cancer initiation and progression 142
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 142
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 142
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 138
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 138
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 136
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 136
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 135
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 133
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 131
Genomic and genetic alterations influence the progression of gastric cancer 130
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 130
Adjuvant chemotherapy with 5-fluorouracil (5-FU) and folinic acid (L-LV) for colorectal carcinoma: preliminary results of a randomized multicenter study of the Gruppo Cooperativo Oncologico Tosco-Umbro (GCOTU) 129
Totale 20.314
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.510
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.510
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021220 0 0 0 0 0 0 0 0 0 0 91 129
2021/20221.089 28 116 62 47 30 69 40 101 65 49 153 329
2022/20233.103 276 533 119 279 219 560 372 183 379 15 71 97
2023/20241.225 50 116 193 37 91 142 99 266 30 78 64 59
2024/20257.632 312 829 501 1.152 2.076 960 149 375 432 207 323 316
2025/20268.486 958 1.217 856 892 975 332 1.230 478 683 623 242 0
Totale 28.643